Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster sold 3,150 shares of Crispr Theraptc stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $18.52, for a total transaction of $58,338.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Thursday, August 17th, Kurt Von Emster sold 34,141 shares of Crispr Theraptc stock. The shares were sold at an average price of $19.06, for a total transaction of $650,727.46.
  • On Tuesday, August 15th, Kurt Von Emster sold 55,569 shares of Crispr Theraptc stock. The shares were sold at an average price of $19.59, for a total transaction of $1,088,596.71.
  • On Tuesday, August 8th, Kurt Von Emster sold 35,473 shares of Crispr Theraptc stock. The shares were sold at an average price of $18.63, for a total transaction of $660,861.99.
  • On Friday, August 4th, Kurt Von Emster sold 50,477 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.81, for a total transaction of $898,995.37.
  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.51, for a total transaction of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.63, for a total transaction of $728,330.56.
  • On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.60, for a total transaction of $579,568.00.
  • On Friday, July 14th, Kurt Von Emster sold 69,859 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.84, for a total transaction of $1,176,425.56.
  • On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.56, for a total transaction of $529,787.52.
  • On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.26, for a total transaction of $69,170.04.

Shares of Crispr Theraptc (NASDAQ:CRSP) traded up 0.11% during mid-day trading on Tuesday, hitting $18.37. 129,610 shares of the company were exchanged. Crispr Theraptc has a 12-month low of $11.63 and a 12-month high of $25.00. The stock’s 50-day moving average price is $17.45 and its 200 day moving average price is $17.52. The stock’s market cap is $745.66 million.

Crispr Theraptc (NASDAQ:CRSP) last issued its earnings results on Thursday, August 10th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.06. The firm had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The firm’s revenue for the quarter was up 350.0% on a year-over-year basis. On average, equities analysts anticipate that Crispr Theraptc will post ($2.43) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/kurt-von-emster-sells-3150-shares-of-crispr-theraptc-crsp-stock/1516351.html.

A number of research analysts have recently commented on CRSP shares. Chardan Capital reissued a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. SunTrust Banks, Inc. started coverage on shares of Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 target price on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. Finally, Cann started coverage on shares of Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating on the stock. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Crispr Theraptc presently has an average rating of “Buy” and an average price target of $21.92.

Hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP boosted its position in shares of Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the period. Monashee Investment Management LLC boosted its position in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the period. Paulson & CO. Inc. purchased a new position in shares of Crispr Theraptc during the first quarter valued at approximately $1,099,000. Credit Suisse AG purchased a new position in shares of Crispr Theraptc during the first quarter valued at approximately $1,742,000. Finally, IHT Wealth Management LLC purchased a new position in shares of Crispr Theraptc during the first quarter valued at approximately $110,000. 24.08% of the stock is owned by hedge funds and other institutional investors.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with Analyst Ratings Network's FREE daily email newsletter.